Pharmacy Times

AUGUST 7, 2025

Extended-release opioids may now be labeled only when non-opioid therapies and immediate-release formulations prove lacking, and labels must caution against abrupt discontinuation in physically dependent patients due to potential withdrawal, uncontrolled pain, or suicidal thoughts. REFERENCES 1. Food and Drug Administration.

Labelling

PharmExec

AUGUST 1, 2025

New labels will include study summaries, improved dosage warnings, and information on overdose reversal agents to enhance patient and healthcare professional awareness. SHOW MORE FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain management.

Medication Labelling

PharmExec

AUGUST 1, 2025

This demonstrated Vizz’s ability to improve near sighted vison within 30 minutes of dosage, with an active timeframe upwards of 10 hours.

Labelling

PharmaTech

AUGUST 1, 2025

Required labeling updates include clearer risk information, stronger warnings, and guidance on opioid use, with a 30-day submission deadline for manufacturers. FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks. References FDA. Press Release. July 31, 2025. Press Release. July 29, 2025.

Medication Labelling

RX Note

DECEMBER 16, 2023

This incident highlights the potential dangers of unconventional medical abbreviations in prescription communication. Similarly, incomplete information about brand names can also lead to medication errors, such as "clopixol accuphase" and "clopixol depot". When doing medication return, please be extra careful too.

Labelling

FADIC

MARCH 22, 2024

Because antipyretics can also be found in many allergy, cold, cough, and flu products, patients should be advised to always read all medication labels prior to administration to avoid therapeutic duplications or possible medication overdose. Follow the recommended dosage and avoid exceeding the daily limit.

Immunity